Dartsbio Pharmaceuticals

Zhongshan, China · Founded 2017 · Privately Held (backing)

Developer of antibody drugs intended to improve the quality of life for cancer patients. Dartsbio Pharmaceuticals is based in Zhongshan, China and was founded in 2017. Its last reported valuation was $15.7 million in May 2020. It has raised $36 million.

Last reported valuation
$15.7M
Oct 2026
Priced at
—
Total raised
$36.0M
Last round
—

Dartsbio Pharmaceuticals key facts

as of Oct 2026
  • Developer of antibody drugs intended to improve the quality of life for cancer patients.
  • Dartsbio Pharmaceuticals is valued at approximately $15.7M as of Oct 2026 (last reported valuation).
  • It has raised $36.0M; the latest was Later Stage VC in Aug 2025.
  • Notable investors include Guangdong Yuecai Venture Capital, Fuho Capital, Zhongshan Xiwan Investment Holding Development, Guangdong Gaowei Investment Management, Jingxing Tiancheng (Ningbo) Private Equity Fund Management — 11 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$15.7M

Dartsbio Pharmaceuticals's last reported valuation, May 2020. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Dartsbio Pharmaceuticals with a free account
  • ·The complete investor list: 11 names
  • ·Watch Dartsbio Pharmaceuticals: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Dartsbio Pharmaceuticals funding rounds

No rounds on record

No funding rounds for Dartsbio Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Dartsbio Pharmaceuticals valuation

Dartsbio Pharmaceuticals's last reported valuation was $15.7 million in May 2020. No priced round, secondary trade or fund mark has surfaced since.

Dartsbio Pharmaceuticals investors

11 investors are on record for Dartsbio Pharmaceuticals, including Guangdong Yuecai Venture Capital, Fuho Capital, Zhongshan Xiwan Investment Holding Development and Guangdong Gaowei Investment Management.

About Dartsbio Pharmaceuticals

Developer of antibody drugs intended to improve the quality of life for cancer patients. The company offers antibody discovery, antibody molecular engineering, and new-generation antibody humanization and develops monoclonal antibody drugs, bispecific antibody drugs, and antibody conjugate drugs (ADC), enabling patients to cure cancer without morphine addiction and tolerance.

Sector
Healthcare
HQ
Zhongshan, China
Founded
2017
Employees
21
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.